X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ALEMBIC PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ALEMBIC PHARMA SANOFI INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 33.8 29.1 116.1% View Chart
P/BV x 6.4 6.6 97.0% View Chart
Dividend Yield % 1.4 0.7 197.5%  

Financials

 SANOFI INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ALEMBIC PHARMA
Mar-16
SANOFI INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560792 576.0%   
Low Rs4,400443 993.2%   
Sales per share (Unadj.) Rs1,028.5167.0 615.8%  
Earnings per share (Unadj.) Rs129.038.2 337.9%  
Cash flow per share (Unadj.) Rs186.042.0 442.9%  
Dividends per share (Unadj.) Rs68.004.00 1,700.0%  
Dividend yield (eoy) %1.50.6 234.3%  
Book value per share (Unadj.) Rs753.684.9 887.7%  
Shares outstanding (eoy) m23.03188.52 12.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.7 117.8%   
Avg P/E ratio x34.716.2 214.7%  
P/CF ratio (eoy) x24.114.7 163.9%  
Price / Book Value ratio x5.97.3 81.8%  
Dividend payout %52.710.5 503.1%   
Avg Mkt Cap Rs m103,174116,383 88.7%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5924,214 85.2%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,68631,487 75.2%  
Other income Rs m70855 1,284.9%   
Total revenues Rs m24,39431,542 77.3%   
Gross profit Rs m5,28110,060 52.5%  
Depreciation Rs m1,313722 181.8%   
Interest Rs m1537 40.8%   
Profit before tax Rs m4,6619,356 49.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6912,160 78.3%   
Profit after tax Rs m2,9707,194 41.3%  
Gross profit margin %22.331.9 69.8%  
Effective tax rate %36.323.1 157.1%   
Net profit margin %12.522.8 54.9%  
BALANCE SHEET DATA
Current assets Rs m15,67315,066 104.0%   
Current liabilities Rs m6,6787,674 87.0%   
Net working cap to sales %38.023.5 161.8%  
Current ratio x2.32.0 119.6%  
Inventory Days Days7667 113.5%  
Debtors Days Days2241 54.9%  
Net fixed assets Rs m8,0988,237 98.3%   
Share capital Rs m230377 61.1%   
"Free" reserves Rs m17,08815,416 110.8%   
Net worth Rs m17,35616,005 108.4%   
Long term debt Rs m00-   
Total assets Rs m25,40024,594 103.3%  
Interest coverage x311.7255.2 122.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 72.8%   
Return on assets %11.829.4 40.0%  
Return on equity %17.144.9 38.1%  
Return on capital %26.958.7 45.9%  
Exports to sales %24.555.7 43.9%   
Imports to sales %28.010.4 268.3%   
Exports (fob) Rs m5,80117,551 33.1%   
Imports (cif) Rs m6,6273,283 201.9%   
Fx inflow Rs m7,14517,811 40.1%   
Fx outflow Rs m6,8465,318 128.7%   
Net fx Rs m29912,493 2.4%   
CASH FLOW
From Operations Rs m3,2269,304 34.7%  
From Investments Rs m-1,555-3,105 50.1%  
From Financial Activity Rs m-1,818-1,959 92.8%  
Net Cashflow Rs m-1474,240 -3.5%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 2.9 496.6%  
FIIs % 14.6 9.1 160.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 13.9 75.5%  
Shareholders   15,184 49,328 30.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 21, 2018 10:53 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS